China Resources Pharmaceutical Group Limited (CHINARES PHARMA, 03320) disclosed unaudited first-quarter results of its 63.22%-owned subsidiary, CR Sanjiu, for the three months ended 31 March 2026.

Revenue and Earnings • Revenue rose to RMB 8.13 billion, up 18.60% from RMB 6.85 billion a year earlier, reflecting solid top-line momentum. • Net profit declined 9.17% year on year to RMB 1.21 billion, compared with RMB 1.33 billion in Q1 2025, indicating margin pressure despite higher sales.

Cash Flow and Liquidity • Net cash used in the quarter was RMB 1.32 billion, reversing from an inflow of RMB 1.25 billion in the prior-year period. • Cash and cash equivalents ended the quarter at RMB 3.20 billion, down 47.63% from RMB 6.11 billion a year earlier.

Balance-Sheet Movements (31 Mar 2026 vs 31 Dec 2025) • Total assets slipped 1.12% to RMB 58.14 billion. • Total liabilities fell 9.16% to RMB 18.47 billion, improving the leverage profile. • Owner’s equity increased 3.13% to RMB 39.68 billion, driven by retained earnings.

Compliance Note The figures are prepared under PRC GAAP and have not been reviewed or audited; adjustments may arise upon audit. The data relate solely to CR Sanjiu and do not present the consolidated position of China Resources Pharmaceutical Group Limited. Shareholders and potential investors are advised to exercise caution when interpreting these unaudited results.